Yuyuan Bioscience Technology

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Astellas To Select Up To Five Targ

ObsEva SA has sold global the rights to its preterm labor (PTL) treatment candidate, ebopiprant, to XOMA Corporation for $15m upfront in a bid to weather its financial troubles, shifting its future

After hitting a stumbling block with US regulators in the summer for its uterine fibroids drug linzagolix, ObsEva SA set up a restructuring plan that would involve "mass dismissals" and the Switzerl

Swiss women's health specialist ObsEva SA had been preparing for the near-term launch of its first commercial product – the GnRH antagonist linzagolix for bleeding associated with uterine fibroids –